UNSPSC 51241134: Pegaptanib sodium

This classification denotes an angiogenesis inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3HP012Q0FH. European Medicines Agency schedules Pegaptanib sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21226. Pegaptanib sodium generally arises in the molecular formula C15H28N3O6(C2H4O)N(C2H4O)N.28NA. The term 'pegaptanib sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule pegaptanib sodium under HS 39072021 and SITC 57419.

Pegaptanib sodium bears US NLM identifiers UMLS ID C0967532 and NCI Concept Code C95230. SMILES: As of Q4 2014, PEGAPTANIB SODIUM remains US FDA's Preferred Term for this commodity.

UNSPSC 51241134 Pegaptanib sodium, a Commodity code, covers procurement of this anti-vascular endothelial growth factor (anti-VEGF) ophthalmic injection used to treat wet age-related macular degeneration (AMD). State and local governments acquire this product through health departments, Medicaid programs, and public health clinics to support treatment protocols for eligible patients. The product is typically procured in unit quantities through standing orders or contract vehicles that bundle pharmaceutical acquisitions, often as part of broader ophthalmic and specialty-drug procurement portfolios managed by state pharmacy programs and public hospital networks.

The source does not identify recent state and local contract opportunities tagged to this code, so current market activity under UNSPSC 51241134 cannot be characterized. When the code appears in state procurement records, it is likely to be embedded in larger pharmaceutical or Medicaid-related solicitations rather than appearing as a standalone RFP, RFQ, IFB, or ITT. Business development professionals should monitor state health department and Medicaid program notices for specialty-drug and ophthalmic-pharmaceutical categories, where pegaptanib sodium may be bundled with other anti-VEGF agents and related treatments.